CTIS2023-506818-45-00进行中（未招募）1 期
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase 1-2a clinical trial for CP-506 that is a drug specific for solid tumours and is activated at low concentrations of oxygen. The trial has 3 modules and 2 parts for each module. Module 1, part A is a dose increase of CP-506 with the possibility to enrol more patients on part B once the recommended phase 2 dose has been determined. Module 2 is the same as module 1 but combining CP-506 with carboplatin and module 3 is combining CP-506 with one Immune Checkpoint Inhibitor.Tumour Agnostic treatment.?Module differentiation:–Module 1 - monotherapy – solid tumour patients with cancer types that are enriched for HRD/FAD defects–Module 2 – combination with Carboplatin – solid tumour patients with cancer types that are enriched for HRD/FAD defects–Module 3 – combination with SOC ICI– solid tumour patients with oligoprogressive disease receiving immune-checkpoint inhibitor (ICI) as standard of careMedDRA version: 24.0Level: LLTClassification code 10084788Term: HRD positive advanced ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000423-12-NLMaastricht University126
招募中
不适用
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIaNL-OMON51911niversiteit Maastricht84
进行中（未招募）
1 期
A study of MP0533 in patients with blood cancer.EUCTR2022-002432-31-NLMolecular Partners AG75
尚未招募
不适用
A phase 1/2a, first-in-human, open-label, multicenter, dose escalation study of MP0533 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)leukemiablood cancer10024324NL-OMON53857Molecular Partners AG23
进行中（未招募）
1 期
A study of MP0533 in patients with blood cancer.relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-002432-31-LTMolecular Partners AG75